Ipsen. Half Year 2015 Results. 31 July IPSEN pour nom de la société - 07/04/2011 / page 1
|
|
- Dorthy Hamilton
- 5 years ago
- Views:
Transcription
1 Ipsen Half Year 2015 Results 31 July 2015 IPSEN pour nom de la société - 07/04/2011 / page 1
2 Disclaimer This presentation includes only summary information and does not purport to be comprehensive. Forward-looking statements, targets and estimates contained herein are for illustrative purposes only and are based on management s current views and assumptions. Such statements involve known and unknown risks and uncertainties that may cause actual results, performance or events to differ materially from those anticipated in the summary information. Actual results may depart significantly from these targets given the occurrence of certain risks and uncertainties, notably given that a new product can appear to be promising at a preparatory stage of development or after clinical trials but never be launched on the market or be launched on the market but fail to sell notably for regulatory or competitive reasons. The Group must deal with or may have to deal with competition from generic that may result in market share losses, which could affect its current level of growth in sales or profitability. The Company expressly disclaims any obligation or undertaking to update or revise any forward-looking statements, targets or estimates contained in this presentation to reflect any change in events, conditions, assumptions or circumstances on which any such statements are based unless so required by applicable law. All product names listed in this document are either licensed to the Ipsen Group or are registered trademarks of the Ipsen Group or its partners. The implementation of the strategy has to be submitted to the relevant staff representation authorities in each country concerned, in compliance with the specific procedures, terms and conditions set forth by each national legislation. 2 Ipsen Half Year 2015 Results 2 Goldman Sachs 35th Annual Global Healthcare Conference June 2014
3 Safe Harbor The Group operates in certain geographical regions whose governmental finances, local currencies or inflation rates could be affected by the current crisis, which could in turn erode the local competitiveness of the Group s products relative to competitors operating in local currency, and/or could be detrimental to the Group s margins in those regions where the Group s drugs are billed in local currencies. In a number of countries, the Group markets its drugs via distributors or agents: some of these partners financial strength could be impacted by the crisis, potentially subjecting the Group to difficulties in recovering its receivables. Furthermore, in certain countries whose financial equilibrium is threatened by the crisis and where the Group sells its drugs directly to hospitals, the Group could be forced to lengthen its payment terms or could experience difficulties in recovering its receivables in full. Finally, in those countries in which public or private health cover is provided, the impact of the financial crisis could cause medical insurance agencies to place added pressure on drug prices, increase financial contributions by patients or adopt a more selective approach to reimbursement criteria. All of the above risks could affect the Group s future ability to achieve its financial targets, which were set assuming reasonable macroeconomic conditions based on the information available today. 3 Ipsen Half Year 2015 Results 3 Goldman Sachs 35th Annual Global Healthcare Conference June 2014
4 Agenda 1 Strategy update Marc de Garidel Chairman and CEO 2 H Operational overview Christel Bories Deputy CEO 3 H Financial overview Aymeric Le Chatelier CFO outlook Marc de Garidel Chairman and CEO 4 Ipsen Half Year 2015 Results 4 Goldman Sachs 35th Annual Global Healthcare Conference June 2014
5 Marc de Garidel Chairman and CEO Strategy update
6 : A refocused strategy within specialty and primary care Global leadership in targeted diseases Focus on GI/OTx Focus on NET/spasticity/Dysport aesthetics (Galderma) Reinforce position in uro-oncology/adult endocrinology Explore adjacent therapeutic areas in GI/orphan cancers Optimize the GI portfolio Diversify into adjacent GI pathologies Reinforce geographical coverage Develop OTx capabilities 6 Ipsen Half Year 2015 Results 6 Goldman Sachs 35th Annual Global Healthcare Conference June 2014 Note: GI:Gastrointestinal, Otx:Dual channel approach (Rx/OTC)
7 2020 outlook showing strong sales growth and profitability momentum Group organic sales Core Operating margin (1) [+6% to +8%] CAGR >+560bps [ 1.8bn to 2bn] 20.4% > 26% 1.3bn E E Potential Business Development to complement 1.8bn to 2.0bn organic sales target 7 Ipsen Half Year 2015 Results 7 Goldman Sachs 35th Annual Global Healthcare Conference June 2014 (1) In percentage of sales
8 H performance Solid Operating performance driven by Specialty sales growth Accelerated Somatuline momentum with significant US launch investment Readiness for US launch of Dysport in AUL spasticity after July FDA approval Continued business development efforts with acquisition of Canbex/Octreopharm 8 Ipsen Half Year 2015 Results 8 Goldman Sachs 35th Annual Global Healthcare Conference June 2014 Note: AUL: Adult Upper Limb,
9 Turnaround of the US platform, with high potential for growth US affiliate sales growth (1) Somatuline US sales growth 64.7% 91.3% 11.5% 31.2% 18.6% 28.6% H H US affiliate to reach breakeven ahead of plan and drive significant profitability increase thanks to Somatuline US platform to be further leveraged with Dysport launch in H2 and potential business development 9 Ipsen Half Year 2015 Results 9 Goldman Sachs 35th Annual Global Healthcare Conference June 2014 (1) Restated for Increlex supply interruption All growth rates at constant currency
10 H Operational overview Christel Bories Deputy CEO
11 Increasing weight of specialty care and the US H sales by segment H sales by geography Top 5 affiliates ~23% Primary care Europe G5 38% 40% Emerging markets 1 France 2 China Specialty care ~77% 13% Developed RoW 9% US 3 US 4 Germany 5 Italy One of the largest emerging market presence in the industry, consolidating US footprint 11 Ipsen Half Year 2015 Results 11 Goldman Sachs 35th Annual Global Healthcare Conference June 2014
12 H Steady Specialty care growth Drug sales H in million euros % excluding foreign exchange impact Somatuline +29.1% 188 Specialty care Decapeptyl Dysport Nutropin Hexvix Increlex +1.7% % +83.1% % +7.0% Specialty care 549m +12.0% Group sales 713.9m +7.9% Primary care Smecta Tanakan Forlax (17.4%) (2.0%) (5.1%) French Primary care: (7.7%) International Primary care: (2.3%) Primary care 165m (1) (3.7%) 12 Ipsen Half Year 2015 Results 12 Goldman Sachs 35th Annual Global Healthcare Conference June 2014 (1) Includes 12.1m of Drug-related sales
13 80% of H1 sales growth coming from Somatuline FY sales in million euros Group sales growth: +7.9% ( 52.5m) at constant currency Somatuline 42.4 Decapeptyl 1.4 Dysport Other Specialty care French PC International PC FX (3.5) (2.9) 22.7 FX Specialty care Primary care H H Somatuline, Group s main driver of growth 13 Ipsen Half Year 2015 Results 13 Goldman Sachs 35th Annual Global Healthcare Conference June 2014
14 Somatuline growth acceleration thanks to successful NET launch Business update Geographic distribution (H1 2015) US: Ipsen present in 40% of NET centers, including all 25 major reference centers Europe: GEP NET approval granted by 21 European countries Increased penetration across geographies 44% 23% 19% 14% G5 (1) Developed RoW United States Emerging markets (2) H performance 3-year growth (cst FX) Overall acceleration of growth due to NET global launch Strong growth in North America, up 88% with positive price impact % % 188 Double digit growth in Europe, notably in Germany, the UK, Spain and France H H H Ipsen Half Year 2015 Results 14 Goldman Sachs 35th Annual Global Healthcare Conference June 2014 (1) France, Germany, UK, Italy, Spain (2) Notably includes China, Russia and Brazil
15 Somatuline accelerated NET penetration in the US and Europe Somatuline US quarterly data, all indications Somatuline Europe G5 (1) quarterly data, all indications sales ( m) market share (%) sales ( m) market share (%) Q Q Q Q Q Q Q Q Q Q Somatuline captured 70% (2) of market growth in Europe and 23% (2) in the US in Q Ipsen Half Year 2015 Results 15 Goldman Sachs 35th Annual Global Healthcare Conference June 2014 Source: IMS MIDAS + Symphony Healthcare (1) G5: France, Germany, UK, Spain, Italy Market share data stop at Q (2) Months of treatment
16 Dysport driven by solid market growth Business update US launch of Dysport in AUL spasticity expected in September 2015 Build-up of US spasticity sales force Geographic distribution (H1 2015) 18% 13% 23% 46% Staffing of European Business unit European launch of additional AUL spasticity indications to start in Q G5 (1) United States Emerging markets (2) Developed RoW H performance 3-year growth (cst FX) Good Galderma performance in aesthetics in a solid underlying market growth Solid performance in emerging countries, notably in Russia +4.3% +7.0% Slowdown of pharmaceutical market in Brazil in Q2 H H H Ipsen Half Year 2015 Results 16 Goldman Sachs 35th Annual Global Healthcare Conference June 2014 (1) France, Germany, UK, Italy, Spain (2) Notably includes China, Russia and Brazil AUL: Adult Upper Limb
17 Decapeptyl facing slowdown in China and price pressure in Europe and Algeria Business update Geographic distribution (H1 2015) Progress on potential combination in breast cancer Launch of 3-month subcutaneous formulation in Europe from July % 8% 44% G5 (1) Developed RoW Emerging markets (2) H performance 3-year growth (cst FX) Lower sales growth in China, facing market slowdown in IVF and price pressure Continued price pressure in Southern Europe and Algeria % % 169 Good growth in UK and Spain H H H Ipsen Half Year 2015 Results 17 Goldman Sachs 35th Annual Global Healthcare Conference June 2014 (1) France, Germany, UK, Italy, Spain (2) Notably includes China, Russia and Brazil (2) Note: IVF: In Vitro Fertilization
18 Primary care impacted by Smecta and Tanakan slowdown Business update Geographic distribution (H1 2015) Start of Tanakan local production in Russia Expected launch of Smecta ready-to-use (liquid) and Strawberry taste in Q in France Accelerated switch of China primary care model to OTx 30% 3% 67% G5 (1) Developed RoW Emerging markets (2) H performance 3-year growth (cst FX) Smecta sales impacted by new manufacturing setup in Algeria and destocking in distribution and price pressure in China Tanakan Russia sales facing out of pocket market slowdown and tough competition (6.9)% (3.7)% France continuous decline with Tanakan market decrease and tail portfolio erosion H H H Ipsen Half Year 2015 Results 18 Goldman Sachs 35th Annual Global Healthcare Conference June 2014 (1) France, Germany, UK, Italy, Spain (2) Notably includes China, Russia and Brazil
19 H1 performance supporting 2015 growth expectations Somatuline to continue delivering growth in NET, both in US and Europe Dysport to benefit from market growth and US launch in AUL spasticity Decapeptyl to benefit from market rebound and new commercial model in China Primary Care growth to recover with seasonality and specific action plans on Tanakan and Smecta Strategic focus and commercial model transformation to support base business growth in both Specialty and Primary Care 19 Ipsen Half Year 2015 Results 19 Goldman Sachs 35th Annual Global Healthcare Conference June 2014 (1) At constant currency (2) In percentage of sales
20 H Financial overview Aymeric Le Chatelier EVP CFO
21 P&L - From sales to Core Operating Income In million euros H H Change % Change Change at constant FX Group sales % +7.9% Other revenues % Revenue % Cost of goods sold (168.3) (155.8) % Selling expenses (259.9) (211.4) % R&D expenses (91.8) (87.6) % G&A expenses (61.3) (51.3) % Other core (2.9) (0.7) -2.2 NA Core Operating Income % Core Operating margin 23.5% 25.4% -1.0 pt 21 Ipsen Half Year 2015 Results 21 Goldman Sachs 35th Annual Global Healthcare Conference June 2014
22 Ipsen exposure to foreign currencies H sales exposure by currency Evolution of major currencies vs. EUR (2) Other (1) million 17% GBP 5% CNY 10% 52% 16% USD EUR Average rates change (H vs. H2 2014) Closing rates change (Jun 2015 vs. Dec 2014) +15.5% +9.3% +14.3%+10.8% +9.0% +8.1% +9.9% -16.8% -6.6% -6.2% USD CNY GBP RUB BRL H sales growth benefiting from strong USD & CNY against EUR Hedging in place to limit impact of key currencies 22 Ipsen Half Year 2015 Results 22 Goldman Sachs 35th Annual Global Healthcare Conference June 2014 (1) Includes RUB, BRL, AUD, PLN and other currencies (2) 1 Foreign Currency Unit = X EUR
23 Other revenues evolution +26.4% In million euros 38.0m 30.1m H H Other Royalties received Increased Adenuric royalty stream Upfront payment received from sale of Ginkor Fort rights Decreasing co-promotion revenues in France & milestones received 23 Ipsen Half Year 2015 Results 23 Goldman Sachs 35th Annual Global Healthcare Conference June 2014
24 Drivers for operating cost evolution COGS ( m) +8.0% R&D ( m) +4.8% % 23.6% 13.7% 12.9% H H Positive mix effect and productivity efforts Selling expenses ( m) H H Tasquinimod discontinuation and lower R&D tax credit G&A ( m) +23.0% % % 36.4% 8.0% 8.6% H H Investment in NET in the US and Europe H H Support function investment and variable compensation 24 Ipsen Half Year 2015 Results 24 Goldman Sachs 35th Annual Global Healthcare Conference June 2014 Note: All ratios in percentage of sales
25 Core Operating margin evolution In million euros Somatuline US Total other Products (1) FX Sales H H COI Margin (as % of sales) 25.4% -1.4% -0.1% -0.4% 23.5% Somatuline US significantly dilutive to Group margin in H Ipsen Half Year 2015 Results 25 Goldman Sachs 35th Annual Global Healthcare Conference June 2014 Note: COI=Core Operating Income (1) Total contribution from all products (ex Somatuline US)
26 P&L - From Core Operating Income to EPS In million euros H H Change % Change Group sales % Core Operating Income % Core Operating margin 23.5% 25.4% -1.0 pt Other non core (6.6) (3.0) -3.6 Restructuring costs (0.7) (12.3) Impairment gain / (losses) (57.0) (0.4) Operating Income % Operating Income margin 14.5% 22.9% -8.4 pts Financial result 3.2 (2.2) +5.4 Income taxes (17.9) (40.7) Share of profit from JV Discontinued operations 0.3 (0.2) +0.5 Consolidated net profit % Consolidated profit margin 12.7% 16.4% -3.7 pts EPS fully diluted ( ) % Core EPS fully diluted ( ) % Consolidated net profit impacted by tasquinimod impairment Core EPS up 7% 26 Ipsen Half Year 2015 Results 26 Goldman Sachs 35th Annual Global Healthcare Conference June 2014
27 H cash flow generation In million euros Free cash flow: 26m (1) Operating cash flow (1) Change in working capital (2) Opening cash Capex -19 Dividends -70 Share Buyback External acquisitions Other Closing cash Dec June 2015 Solid free cash flow generation despite higher working capital Closing cash impacted by dividends, share buyback and external acquisitions 27 Ipsen Half Year 2015 Results 27 Goldman Sachs 35th Annual Global Healthcare Conference June 2014 (1) Before restructuring cost (2) Excluding milestone amortization
28 Balance sheet evolution ASSETS LIABILITIES In million euros FY 2014 H In million euros FY 2014 H Goodwill Capital and reserves 1, ,132.0 Other intangible assets Non-controlling interests Property, plant and equipment Investments in companies accounted for using the equity method Total equity 1, , Provisions Other non current assets Financial liabilities Non-current assets 1, ,088.2 Other non current liabilities Current assets Non-current liabilities Incl. Cash and cash equivalents Current liabilities Total Assets 1, ,760.8 Total Liabilities 1, , Ipsen Half Year 2015 Results 28 Goldman Sachs 35th Annual Global Healthcare Conference June 2014 Solid balance sheet with net cash Intangibles impacted by tasquinimod impairment
29 H1 2015: Key financial achievements Group sales up 7.9% (1) driven by specialty care growth of 12% (1), notably Somatuline in the US and Europe Core Operating Income up 3.5%, or 23.5% margin (2), due to high investment for NET launch, notably in the US Consolidated net profit of 90.5m, impacted by tasquinimod impairment Robust Core EPS of 1.50, up 7.0% year-on-year Sound operating cash flow generation Closing net cash balance of 88m 29 Ipsen Half Year 2015 Results 29 Goldman Sachs 35th Annual Global Healthcare Conference June 2014 (1) At constant currency (2) In percentage of sales
30 Marc de Garidel Chairman and CEO 2015 outlook
31 Major R&D and regulatory milestones to come R&D H H Dysport PLL PhIII topline results Dysport ALL PhIII topline results Telotristat etiprate (LX1032) SOMScan PhIII results Ph3 initiation SOMther Ph1 initiation Syntaxin compound Ph1 initiation Regulatory/ Commercial DNG positive regulatory feedback Dysport PLL US filing Dysport AUL US approval Dysport AUL US launch Somatuline GEP NETs global launch Dysport ALL US filing Dysport Solution Europe/Brazil filing in cervical dystonia 31 Ipsen Half Year 2015 Results 31 Goldman Sachs 35th Annual Global Healthcare Conference June 2014 Note: AUL: Adult Upper Limb, PLL: Pediatric Lower Limb, ALL: Adult Lower Limb
32 Financial objectives upgraded for 2015 Specialty care Drug sales Growth 14.0%, year-on-year Driven by the launch of Somatuline in neuroendocrine tumors in the US and Europe Primary care Drug sales Decline of -3.0% to 0.0%, year-on-year From 2015 onwards, drug-related sales (active substances and raw materials) to be recorded in the Primary care sales line Core Operating Income 22.0% of Group sales Reflecting the growth of Specialty care and the investments required to support the global launch of Somatuline and Dysport in the US 32 Ipsen Half Year 2015 Results 32 Goldman Sachs 35th Annual Global Healthcare Conference June 2014 Note: Sales objectives are set at constant currency
33 2015 guidance showing strong sales and profitability momentum Group organic sales Core Operating margin (1) +9.5% (2) +160bps 1.40 bn (3) 22% 1.27bn 20.4% E E 33 Ipsen Half Year 2015 Results 33 Goldman Sachs 35th Annual Global Healthcare Conference June 2014 (1) In percentage of sales (2) At constant currency, based on the lower range of the specialty and primary care guidance (3) Excluding foreign exchange impact
34 Key takeaways 1 Focused Strategy on niche disease areas with 26% minimum profitability target by double digit organic sales growth and significant profitability enhancement thanks to Somatuline launch 3 Continuous business development effort to leverage portfolio and geographies Ipsen committed to deliver superior shareholder value 34 Ipsen Half Year 2015 Results 34 Goldman Sachs 35th Annual Global Healthcare Conference June 2014
35 Thank you
Ipsen 2015 Financial Results
Ipsen 2015 Financial Results 1 March 2016 IPSEN pour nom de la société - 07/04/2011 / page 1 Disclaimer This presentation includes only summary information and does not purport to be comprehensive. Forward-looking
More informationIpsen 2015 Full Year Financial Results
Ipsen 2015 Full Year Financial Results Full Year Results Roadshow - New York / Boston, March 7-8, 2016 IPSEN pour nom de la société - 07/04/2011 / page 1 Disclaimer This presentation includes only summary
More informationIpsen. Jefferies Healthcare Conference. November 17, IPSEN pour nom de la société - 07/04/2011 / page 1
Ipsen Jefferies Healthcare Conference November 17, 2016 IPSEN pour nom de la société - 07/04/2011 / page 1 Disclaimer This presentation includes only summary information and does not purport to be comprehensive.
More informationIpsen 2016 Healthcare Conference
Ipsen 2016 Healthcare Conference Jefferies - June 2016 IPSEN pour nom de la société - 07/04/2011 / page 1 Disclaimer This presentation includes only summary information and does not purport to be comprehensive.
More informationIpsen Half Year 2016 Financial Results
Ipsen Half Year 2016 Financial Results 28 July 2016 IPSEN pour nom de la société - 07/04/2011 / page 1 Disclaimer This presentation includes only summary information and does not purport to be comprehensive.
More informationIpsen 2016 First Half Financial Results
Ipsen 2016 First Half Financial Results Half-Year Results Roadshow - New York / Boston, August 29-30, 2016 IPSEN pour nom de la société - 07/04/2011 / page 1 Disclaimer This presentation includes only
More informationIpsen 2012 Financial Results
Ipsen 2012 Financial Results IPSEN pour nom de la société - 07/04/2011 / page 1 Disclaimer This presentation includes only summary information and does not purport to be comprehensive. Forward-looking
More informationIpsen FY 2017 Results. February 15, 2018
Ipsen FY 2017 Results February 15, 2018 Disclaimer & Safe Harbor This presentation includes only summary information and does not purport to be comprehensive. Forward-looking statements, targets and estimates
More informationIpsen FY 2018 Results. February 14, 2019
Ipsen FY 2018 Results February 14, 2019 Disclaimer & Safe Harbor This presentation includes only summary information and does not purport to be comprehensive. Forward-looking statements, targets and estimates
More informationIpsen Q Sales. April 26, 2018
Ipsen Q1 2018 Sales April 26, 2018 Disclaimer & Safe Harbor This presentation includes only summary information and does not purport to be comprehensive. Forward-looking statements, targets and estimates
More informationIpsen 31 st Annual J.P. Morgan Healthcare Conference
Ipsen 31 st Annual J.P. Morgan Healthcare Conference Marc de Garidel President and CEO IPSEN pour nom de la société - 07/04/2011 / page 1 Disclaimer This presentation includes only summary information
More informationIpsen H Results. July 27, 2017
Ipsen H1 2017 Results July 27, 2017 Disclaimer & Safe Harbor This presentation includes only summary information and does not purport to be comprehensive. Forward-looking statements, targets and estimates
More informationIpsen Q Sales. October 25, 2018
Ipsen Q3 2018 Sales October 25, 2018 Disclaimer & Safe Harbor This presentation includes only summary information and does not purport to be comprehensive. Forward-looking statements, targets and estimates
More informationIpsen H Results. July 26, 2018
Ipsen H1 2018 Results July 26, 2018 Disclaimer & Safe Harbor This presentation includes only summary information and does not purport to be comprehensive. Forward-looking statements, targets and estimates
More informationFirst half 2009: confirming Ipsen s specialist care globalisation. August 28, 2009
First half 2009: confirming Ipsen s specialist care globalisation August 28, 2009 Disclaimer This presentation includes only summary information and does not purport to be comprehensive. Forward-looking
More informationIpsen. Jefferies 2012 Global Healthcare Conference London, November 14 th, 2012
Ipsen Jefferies 2012 Global Healthcare Conference London, November 14 th, 2012 Pierre Kemula VP, Corporate Finance, Treasury and Financial Markets Stéphane Durant des Aulnois Investor Relations Manager
More informationIpsen First Half Financial Results. Bryan Garnier Roadshow - Paris, September 1-2, IPSEN pour nom de la société - 07/04/2011 / page 1
Ipsen 2014 First Half Financial Results Bryan Garnier Roadshow - Paris, September 1-2, 2014 IPSEN pour nom de la société - 07/04/2011 / page 1 Disclaimer This presentation includes only summary information
More informationFirst half 2011 Results and Perspectives
First half 2011 Results and Perspectives First Half 2011 Results Presentation August 30, 2011 Disclaimer This presentation includes only summary information and does not purport to be comprehensive. Forwardlooking
More informationIpsen 2011 Financial Results Roadshow. Full Year 2011 Results
Ipsen 2011 Financial Results Roadshow Full Year 2011 Results Disclaimer This presentation includes only summary information and does not purport to be comprehensive. Forward-looking statements, targets
More informationGoldman Sachs 34th Annual Global Healthcare Conference
Goldman Sachs 34th Annual Global Healthcare Conference June 12, 2013 Marc de Garidel President and CEO IPSEN pour nom de la société - 07/04/2011 / page 1 Disclaimer This presentation includes only summary
More informationIpsen delivers strong results for the first half of 2018 with sales growth of 21.5% 1 and upgrades its guidance for full year 2018
Ipsen delivers strong results for the first half of 2018 with sales growth of 21.5% 1 and upgrades its guidance for full year 2018 Sales growth of 26.7% 1 for Specialty Care and 2.0% 1,2 for Consumer Healthcare
More information2015 HALF YEAR FINANCIAL REPORT
2015 HALF YEAR FINANCIAL REPORT Ipsen First-Half 2015 Financial Report - 1 / 39 2015 HALF YEAR FINANCIAL REPORT SUMMARY I - 2015 HALF YEAR CONDENSED CONSOLIDATED FINANCIAL STATEMENTS 3 II - ACTIVITY REPORT
More informationIpsen s First Half 2016 Results
PRESS RELEASE Ipsen s First Half 2016 Results Group sales up 9.7% 1 driven by Specialty Care growth of 14.3% 1, notably due to strong performance of Somatuline Core Operating Income up 12.6% fueled by
More informationPRESS RELEASE. Ipsen delivers strong 2018 results and expects continued sales and profit growth in 2019
PRESS RELEASE Ipsen delivers strong 2018 results and expects continued sales and profit growth in 2019 Paris (France), 14 February 2019 Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-driven biopharmaceutical
More informationIpsen reports strong first quarter 2018 sales growth of 23.1% at constant exchange rates
PRESS RELEASE Ipsen reports strong first quarter 2018 sales growth of 23.1% at constant exchange rates Paris (France), 26 April 2018 - Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-driven biopharmaceutical
More information2010 Financial Results
2010 Financial Results ODDO Roadshow Full Year 2010 Results Paris 7th March 2011 Mr Marc de Garidel Chairman and Chief Executive Officer Mr Claude Bertrand EVP Chief Scientific Officer Mrs Claire Giraut
More informationIpsen s first nine months of 2008 sales and update of Group financial objectives
Press release Ipsen s first nine months of 2008 sales and update of Group financial objectives Continued strength: +10.9% performance (1) sales growth, +7.0% reported (2) Acceleration of growth in speciality
More informationExtract of audited consolidated results for the full year 2017 and 2016
PRESS RELEASE Ipsen delivers strong 2017 results with 21.1% 1 sales growth and Core operating margin increase of 3.4 points and expects significant further growth in sales and margin in 2018 Paris (France),
More informationFinancial Information
Accelerating & profit in H1: Revenue up +4% reported, Adj. EBITA +8%, Net Income +18%, FCF +15% H1 revenue of 12.2bn, +2.7% organic, +4.1% outside Infrastructure H1 adj. EBITA margin up 60bps 1 org., to
More informationIpsen s first nine months of 2007 sales
Press release Ipsen s first nine months of 2007 sales +5.5% growth in Group sales, +7.2% growth in volume sold Continued growth outside the Major Western European Countries: +12.1% Financial and sales
More informationJuly 26, 2017 LafargeHolcim Ltd 2015
Second Quarter 2017 Results Beat Hess, Chairman and Interim CEO Roland Köhler, Interim COO and Regional Head of Europe, Australia/NZ & Trading Ron Wirahadiraksa, CFO July 26, 2017 LafargeHolcim Ltd 2015
More informationAnnual shareholder s meeting. 6 june 2007
Annual shareholder s meeting 6 june 2007 Disclaimer This presentation includes only summary information and does not purport to be comprehensive. Forward-looking statements, targets and estimates contained
More informationFull year 2006 results
Full year 2006 results Roadshow Goldman Sachs Mr Jean-Luc Bélingard Chief Executive Officer Mr Jacques-Pierre Moreau Chief Scientific Officer Mr David Schilansky Investor Relations Officer New York - April,
More informationFinancial Information
Financial Information H1 revenues reached 12.8bn up 9.8%, flat org. in Q2 Adj. EBITA reached 1.6bn, up 6.4%, Adj. EBITA margin flat excl. Invensys in a challenging environment 2015 targets: Around flat
More information2017 FULL YEAR RESULTS. February 28,
2017 FULL YEAR RESULTS February 28, 2018 1 Disclaimer This presentation contains both historical and forward-looking statements. These forward-looking statements are based on Carrefour management's current
More informationPERFORMANCE AND TRAJECTORY
PERFORMANCE AND TRAJECTORY José (Joe) E. Almeida Chairman, President and CEO May 21, 2018 Safe Harbor Statement This presentation includes forward-looking statements concerning Baxter s financial results,
More informationAnalysts Meeting Q Bernard Charlès, President and CEO Thibault de Tersant, Senior EVP, CFO
Analysts Meeting Q3 2015 Bernard Charlès, President and CEO Thibault de Tersant, Senior EVP, CFO 1 Forward Looking Information Statements herein that are not historical facts but express expectations or
More informationConsolidated Financial Results FY2015 Q2
Consolidated Financial Results FY2015 Q2 October 30, 2015 Rudolf van Houten Acting CFO & Group Financial Controller Important Notice Forward-Looking Statements This presentation contains forward-looking
More informationFull-year results 2018
Full-year results 2018 Investor Call 1 Disclaimer This presentation contains forward looking statements which reflect Management s current views and estimates. The forward looking statements involve certain
More informationFinancial results & business update. Quarter ended 30 September October 2016
Financial results & business update Quarter ended 30 September 2016 19 October 2016 Disclaimer 3 Any remarks that we may make about future expectations, plans and prospects for the company constitute forward-looking
More informationCombined Shareholders Meeting
Combined Shareholders Meeting June 7, 2017 This is a free translation into English of the slides presented at the Shareholders meeting, for the convenience of English-speaking users. Disclaimer The forward-looking
More information2015 Half-Year Results. July 30, 2015
201 Half-Year Results July 30, 201 AGENDA 1 2 3 4 HIGHLIGHTS H1 201 ACHIEVEMENTS ONGOING DEVELOPMENT 201 TARGETS 2 1 HIGHLIGHTS 3 1 HIGHLIGHTS HIGHLIGHTS H1 201 achievements Total growth in sales: +8.4%
More informationForward-Looking Statements. Consolidated Financial Results for the 3rd Quarter of Fiscal Year François-Xavier Roger Chief Financial Officer
Consolidated Financial Results for the 3rd Quarter of Fiscal Year 2014 François-Xavier Roger Chief Financial Officer February 5, 2015 Forward-Looking Statements This presentation contains forward-looking
More information2014 HALF YEAR FINANCIAL REPORT
2014 HALF YEAR FINANCIAL REPORT Ipsen First-Half 2014 Financial Report - 1 / 47 2014 HALF YEAR FINANCIAL REPORT SUMMARY I - 2014 HALF YEAR CONDENSED CONSOLIDATED FINANCIAL STATEMENTS 3 II - ACTIVITY REPORT
More informationPress release 8 March RESULTS
2011 RESULTS Slight growth in sales, supported by emerging markets Current Operating Income of 2.2bn Net income, Group share, down 14%, impacted by significant one off elements Net debt reduced by more
More informationFull-year results 2017 Conference. February 15, 2018 Nestlé full-year results 2017
Full-year results 2017 Conference 1 Disclaimer This presentation contains forward looking statements which reflect Management s current views and estimates. The forward looking statements involve certain
More informationFY 2017 FINANCIAL RESULTS. Milan February 27 th, 2018
FY 2017 FINANCIAL RESULTS Milan February 27 th, 2018 1 AGENDA FY 2017 Highlights o o Group overview Results by business Financial results Appendix 2 Key Achievements of 2017 General Cable Acquisition Leadership
More informationFinancial results & business update. Quarter and year ended 31 December February 2017
Financial results & business update Quarter and year ended 31 December 2016 14 February 2017 Disclaimer 3 Any remarks that we may make about future expectations, plans and prospects for the company constitute
More informationRENAULT GROUP 2012 FINANCIAL RESULTS
RENAULT GROUP 2012 FINANCIAL RESULTS DISCLAIMER Information contained within this document may contain forward looking statements. Although the Company considers that such information and statements are
More informationHalf Year 2013 Earnings
Half Year 2013 Earnings August 2, 2013 Presentation Table of contents Introduction & highlights Page A4 by Henri de Castries, Chairman and CEO financial performance by Denis Duverne, Deputy CEO & Gérald
More informationCapgemini records an excellent performance in 2017 with growth acceleration fueled by Digital and Cloud
Press relations: Florence Lièvre Tel.: +33 1 47 54 50 71 florence.lievre@capgemini.com Investor relations: Vincent Biraud Tel.: +33 1 47 54 50 87 vincent.biraud@capgemini.com Capgemini records an excellent
More informationFinancial results & business update. Quarter and year ended 31 December February 2016
Financial results & business update Quarter and year ended 31 December 2015 11 February 2016 Disclaimer 3 Any remarks that we may make about future expectations, plans and prospects for the company constitute
More informationFor personal use only
ASX / Media release 14 February 2017 COCHLEAR FINANCIAL RESULTS FOR THE SIX MONTHS ENDED DECEMBER 2016 Positive momentum continues across all markets Net profit of $111.4m, up 19% Cochlear implant units
More informationFIRST-HALF 2018 RESULTS DOUBLE-DIGIT GROWTH IN SALES** AND OPERATING INCOME IN THE FIRST HALF UPGRADED FULL-YEAR GUIDANCE
Nanterre (France), July 20, 2018 FIRST-HALF 2018 RESULTS DOUBLE-DIGIT GROWTH IN SALES** AND OPERATING INCOME IN THE FIRST HALF UPGRADED FULL-YEAR GUIDANCE in m H1 2017* H1 2018 Change Sales 8,545.2 8,991.3
More information2011 Full Year Results
2011 Full Year Results Basel: February 8, 2012 Safe harbor This document contains forward-looking statements, which can be identified by terminology such as expect, would, will, potential, plans, prospects,
More informationFULL-YEAR 2017 RESULTS
Nanterre (France), February 16, 2018 FULL-YEAR 2017 RESULTS STRONG PERFORMANCE IN 2017 WITH OPERATING MARGIN AT 7% OF SALES IN H2 2018 GUIDANCE AHEAD OF ROADMAP RECORD ORDER INTAKE AT 62BN, UP 9BN ACCELERATION
More informationFinancial results & business update. Quarter ended 30 September October 2017
Financial results & business update Quarter ended 30 September 2017 18 October 2017 Disclaimer 3 Any remarks that we may make about future expectations, plans and prospects for the company constitute forward-looking
More informationForward Looking Statements
Kingspan 2015 Full Year Results 22 nd February 2016 Disclaimer Forward Looking Statements This presentation contains certain forward-looking statements including, without limitation, regarding the Group
More informationH Financial Results. Milan July 28th, 2016
H1 2016 Financial Results Milan July 28th, 2016 Agenda H1 2016 Highlights o o o Group overview Results by business Outlook Financial results Appendix H1 2016 Financial Results 2 H1 2016 Highlights Organic
More informationBIC GROUP PRESS RELEASE CLICHY 01 AUGUST 2018 FIRST HALF 2018 RESULTS CHALLENGING TRADING ENVIRONMENT 2018 OUTLOOK UNCHANGED
BIC GROUP PRESS RELEASE CLICHY 01 AUGUST 2018 Follow BIC latest news on FIRST HALF 2018 RESULTS CHALLENGING TRADING ENVIRONMENT 2018 OUTLOOK UNCHANGED H1 Net Sales: 959.3 million euros, down 1.9% on a
More informationGoldman Sachs 2012 Leveraged Finance Healthcare Conference MATTHEW WALSH SVP FINANCE & CFO
Goldman Sachs 2012 Leveraged Finance Healthcare Conference MATTHEW WALSH SVP FINANCE & CFO 05.01.2012 Forward Looking Statements This presentation contains both historical and forward-looking statements.
More information2007 Revenue and Results. 2007: strong increase in results Strengthened growth momentum. February 15 th, 2008
2007 Revenue and Results 2007: strong increase in results Strengthened growth momentum February 15 th, 2008 2007 revenue and results Agenda A successful 2007 Be the recognized industry leader John Glen
More informationPhilips Healthcare Financial Update. Ingo Bank, CFO Philips Healthcare
Philips Healthcare Financial Update Ingo Bank, CFO Philips Healthcare Key takeaways Growth outlook: Slow start into first half of 2013 Solid outlook for growth geographies North America market challenging
More information2010 Annual Results. February 10, 2011
2010 Annual Results February 10, 2011 Disclaimer This presentation contains forward-looking statements. The use of the words "aim(s)," "expect(s)," "feel(s)," "will," "may," "believe(s)," "anticipate(s)"
More informationPHOTOCURE ASA RESULTS FOR FIRST QUARTER MAY Kjetil Hestdal, MD, President & CEO Erik Dahl, CFO
PHOTOCURE ASA RESULTS FOR FIRST QUARTER 2018 23 MAY 2018 Kjetil Hestdal, MD, President & CEO Erik Dahl, CFO DISCLAIMER The information included in this Presentation contains certain forward-looking statements
More informationFinancial Targets through 2022: Focus on Value Creation
Financial Targets through 2022: Focus on Value Creation /////////// Capital Markets Day London, December 5, 208 Wolfgang Nickl CFO Bayer AG Disclaimer Cautionary Statements Regarding Forward-Looking Information
More informationFY 2017 Results. March 6, 2018
FY 2017 Results March 6, 2018 Forward looking statements This Presentation may include forward-looking statements. Forward-looking statements are statements regarding or based upon our management s current
More informationHalf year financial report
2009 Half year financial report 2009 HALF YEAR FINANCIAL REPORT SUMMARY I CONDENSED CONSOLIDATED FINANCIAL STATEMENTS 3 II ACTIVITY REPORT 35 III - INFORMATION ON RELATED PARTIES 47 IV RISKS FACTORS 48
More informationMerck FY/Q Financial Summary for Investors and Analysts
Merck FY/Q4 2018 Financial Summary for Investors and Analysts A year of investments and delivery on Guidance Healthcare Solid organic growth of 5.2% driven by resilient core business with 3% organic growth
More informationIpsen s first quarter 2013 sales. Group sales up 5.3% 1. Solid specialty care growth, up 8.0% 1. Somatuline up 12.6% 1 Dysport up 8.
PRESS RELEASE Ipsen s first quarter 2013 sales Group sales up 5.3% 1 Solid specialty care growth, up 8.0% 1 Somatuline up 12.6% 1 Dysport up 8.4% 1 Resilience of Primary care, down 1.9% 1, supported by
More informationFinancial results & business update. Quarter ended 31 March April 2018
Financial results & business update Quarter ended 31 March 2018 18 April 2018 Disclaimer 3 Any remarks that we may make about future expectations, plans and prospects for the company constitute forward-looking
More informationFull Year 2008 Earnings
Full Year 2008 Earnings Olivier Piou, CEO Jacques Tierny, CFO March 19, 2009 www.gemalto.com Disclaimer Forward-Looking Statements This communication contains certain statements that are neither reported
More informationInterim Report Q Conference call May 4, 2017
Interim Report Q1 2017 Conference call May 4, 2017 Safe Harbor Statement 2 The forward-looking statements in this interim report reflect the management's current expectations of certain future events and
More informationQ Results. October 29, 2018
Q3 2018 Results October 29, 2018 Forwardlooking Statements This presentation contains a number of forwardlooking statements. Words, and variations of words, such as will, expect, may, should, believe,
More informationAnnual General Meeting of Shareholders
Annual General Meeting of Shareholders Nancy McKinstry CEO and Chairman of the Executive Board April 20, 2007 Amsterdam Annual General Meeting of Shareholders April 20, 2007 - Amsterdam 1 Agenda Opening
More informationQ4 and Full Year 2018 Earnings Call
We make healthy possible Q4 and Full Year 2018 Earnings Call Financial Results and Business Update February 28, 2019 Safe Harbor Statement Safe Harbor Statement Certain statements contained herein, regarding
More information2017 Full Year Results. Tuesday 21 November 2017
2017 Full Year Results Tuesday 21 November 2017 Disclaimer Certain information included in the following presentation is forward looking and involves risks, assumptions and uncertainties that could cause
More informationPAREXEL INTERNATIONAL
PAREXEL INTERNATIONAL Jefferies Healthcare Conference June 8, 2016 2015 PAREXEL INTERNATIONAL CORP. SAFE HARBOR This presentation contains forward-looking statements within the meaning of Section 27A of
More informationZEBRA TECHNOLOGIES FIRST QUARTER 2016 RESULTS May 10, 2016
ZEBRA TECHNOLOGIES FIRST QUARTER 2016 RESULTS May 10, 2016 Anders Gustafsson Chief Executive Officer Mike Smiley Chief Financial Officer 2 Safe Harbor Statement Statements made in this presentation which
More informationH RESULTS Continued improvement in performance Upgraded full-year guidance
H1 2018 RESULTS Continued improvement in performance Upgraded full-year guidance July 20, 2018 The 2018 half-year consolidated financial statements have been approved by the Board of Directors at its meeting
More informationWilliam Blair Growth Stock Conference. Eric Dey EVP & CFO
William Blair Growth Stock Conference Eric Dey EVP & CFO June 12, 2018 Safe Harbor Provision This presentation contains forward-looking statements within the meaning of the federal securities laws. Statements
More informationREXEL. Q3 & 9-month 2009 results. November 12, 2009
REXEL Q3 & 9-month 2009 results November 12, 2009 Q3 2009 & 9-month results Q3 and 9-month 2009 at a glance Financial review Outlook 3 Q3 & 9-month 2009 at a glance Q3 & 9-month 2009 highlights: Quarter-on-quarter
More informationWilliam Blair 35 th Annual Growth Stock Conference. June 9, 2015 NYSE: Q. Copyright 2014 Quintiles
William Blair 35 th Annual Growth Stock Conference June 9, 2015 Copyright 2014 Quintiles NYSE: Q Forward Looking Statements and Use of Non-GAAP Financial Measures This presentation contains forward-looking
More informationHalf-year 2012 Results. August 1, 2012
Half-year 2012 Results August 1, 2012 Disclaimer All forward-looking statements are Schneider Electric management s present expectations of future events and are subject to a number of factors and uncertainties
More informationH FINANCIAL RESULTS. Milan September 18 th, 2018
H1 2018 FINANCIAL RESULTS Milan September 18 th, 2018 1 AGENDA H1 2018 Highlights o o o Group overview Results by business Outlook Financial results Appendix 2 H1 2018 Financial Highlights Organic sales
More informationFY 2014 Results Presentation. Uwe Röhrhoff, CEO Rainer Beaujean, CFO Duesseldorf, February 11, 2015
FY 2014 Results Presentation Uwe Röhrhoff, CEO Rainer Beaujean, CFO Duesseldorf, February 11, 2015 Disclaimer 1. This presentation may contain certain forward-looking statements, including assumptions,
More information2017 Full Year Results
2017 Full Year Results Title of the presentation 2 lines Location, Date, Author Paris February 15 th, 2018 Disclaimer This presentation may contain forward-looking statements, Such statements may include
More informationFinancial results & business update
Financial results & business update Quarter ended 31 March 2019 16 April 2019 Disclaimer Any remarks that we may make about future expectations, plans and prospects for the company constitute forward-looking
More information2018 Half year results 20 July 2018
2018 Half year results 20 July 2018 www.thalesgroup.com H1 2018 business environment Aerospace Ground transportation Defence & Security Aeronautics: positive dynamics for cockpit avionics and in-flight
More informationFirst-Quarter 2018 Earnings
First-Quarter 208 Earnings Baxter International Inc. April 26, 208 Safe Harbor Statement This presentation includes forward-looking statements concerning Baxter s financial results, business development
More informationSociété Générale Conference
BIC Group Société Générale Conference Nice June 6, 2008 1 Our strategy Support core products Meet consumers needs and desires through innovative products Improve our quality & manufacturing efficiency
More informationFull Year 2017 Earnings. Press Conference February 22, 2018
Full Year 2017 Earnings Press Conference February 22, 2018 IMPORTANT LEGAL INFORMATION AND CAUTIONARY STATEMENTS CONCERNING FORWARD-LOOKING STATEMENTS Certain statements contained herein may be forward-looking
More informationStrategic Roadmap Update and FY2015 Q1 Consolidated Financial Results Important notice Forward-Looking Statements Medical Information
Strategic Roadmap Update and FY2015 Q1 Consolidated Financial Results Christophe Weber, President & CEO Rudolf van Houten, Acting CFO & Group Financial Controller July 30, 2015 Important notice Forward-Looking
More information2012 First-Half Review. Paris - September 5, 2012
2012 First-Half Review Paris - September 5, 2012 Disclaimer This presentation contains information, assumptions and estimates that were used by the Company to determine its objectives on a reasonable basis.
More informationQ4 and Full Year 2007 Earnings. February 8, 2008
Q4 and Full Year 2007 Earnings February 8, 2008 Safe Harbor For Forward Looking Statements Except for historical information, all other information in this presentation consists of forwardlooking statements
More informationTokyo, February 7, 2019 Highlights 2018 Earnings Report 2018 results from January 1 to December 31: Adjusted operating profit at constant FX increased
Tokyo, February 7, 2019 Highlights 2018 Earnings Report 2018 results from January 1 to December 31: Adjusted operating profit at constant FX increased 8.9% year on year or 1.7% on a reported basis. Strong
More informationRELX Group interim results 2017 Erik Engstrom, CEO Nick Luff, CFO
RELX Group interim results Erik Engstrom, CEO Nick Luff, CFO FORWARD-LOOKING STATEMENTS This presentation contains forward-looking statements within the meaning of Section 27A of the US Securities Act
More informationABB Q results Joe Hogan, CEO Michel Demaré, CFO
October 27, 2011 ABB Q3 2011 results Joe Hogan, CEO Michel Demaré, CFO ABB Group Q3 2008 investor presentation October 26, 2011 Chart 1 Safe-harbor statement This presentation includes forward-looking
More informationImportant notice. Consolidated Financial Results for FY2014 and Guidance for FY2015. François-Xavier Roger Chief Financial Officer
Consolidated Financial Results for FY2014 and Guidance for FY2015 François-Xavier Roger Chief Financial Officer May 15, 2015 Important notice Forward-Looking Statements This presentation contains forward-looking
More informationAEGIS GROUP PLC 2008 ANNUAL RESULTS. 19 March 2009
AEGIS GROUP PLC 2008 ANNUAL RESULTS 19 March 2009 AGENDA OVERVIEW OF RESULTS John Napier FINANCIAL REVIEW Alicja Lesniak OUTLOOK John Napier Q&A Aegis Group plc Page 2 OVERVIEW OF RESULTS John Napier,
More information